Complement: Structure, functions, evolution, and viral molecular mimicry

Immunologic Research

Volumn 27, Issue 2-3, 2003, Pages 367-385

  Mastellos, Dimitrios ^a   Morikis, Dimitrios ^b   Isaacs, Stuart N ^c   Holland, M Claire ^a   Strey, Cristoph W ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of California Riverside   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Complement; Evolution; Immune evasion; Inhibitors; Proteomics; Regeneration

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; DEUTERIUM; HYDROGEN; PROTEIN;

ANTIGEN ANTIBODY COMPLEX; CELL REGENERATION; COMPLEMENT SYSTEM; HEMATOPOIETIC SYSTEM; HUMORAL IMMUNITY; IMMUNE RESPONSE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOMICS; RADIATION SCATTERING; REGENERATION; REVIEW; VIRUS IMMUNITY;

EID: 0042520964     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:27:2-3:367     Document Type: Review

References (98)

1. Sunyer JO, Lambris JD Evolution and diversity of the complement system of poikilothermic vertebrates. Immunol Rev 1998;166:39-57.
2. Lambris JD, ed. The third component of complement: chemistry and biology. Curr Topics Microb Immunol 1990;153:45-72.
3. Volanakis JE: Overview of the complement system; in (Volanakis JE, Frank M, eds), The Human Complement System in Health and Disease Marcel Dekker Inc. 1998, pp. 9-32.
4. Dempsey PW Allison MD, Akkaraju S, et al.: C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996;271:348-350.
5. Lambris JD: The multifunctional role of C3, the third component of complement. Immunol Today 1988;9:387-393.
6. Muller-Eberhard HJ: Molecular organization and function of the complement system. Annu Rev Biochem 1988;57:321-347.
7. Lambris JD, Sahu A, Wetsel R: (1998) The chemistry and biology of C3,C4, and C5; in Volanakis JE, Frank M, (eds) The Human Complement System in Health and Disease, Marcel Dekker Inc., 1998, pp. 83-118.
8. Perkins SJ, Sim RB: Molecular modelling of human complement component C3 and its fragments by solution scattering. Eur J Biochem 1986;157:155-168.
9. Wetsel RA: Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995;7:48-53.
10. Alsenz J, Avila D, Huemer HP, et al.: Phylogeny of the third component of complement, C3: Analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species. Develop Compar Immunol 1992;16:63-76.
11. Lambris JD, Alsenz J, Schulz TF, et al.: Mapping of the properdin-binding site in the third component of complement. Biochem J 1984;217:323-326.
12. Lambris JD, Lao Z, Oglesby TJ, et al.: Dissection of CR1, factor H, MCP, and factor B binding and functional sites in third complement component. J Immunol 1996;156:4821-4832.
13. Mastellos D, Lambris JD: Complement: more than a 'guard' against invading pathogens? Trends Immunol 2002;23:485-491.
14. DiScipio RG, Smith CA, Müller-Eberhard HJ, et al.: The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem 1983;258:10,629-10,636.
15. Morgan BP: Regulation of the complement membrane attack pathway. Crit Rev Immunol 1999;19:173-198.
16. Halperin JA, Taratuska A, Nicholsonweller A: Terminal Complement Complex C5b-9 Stimulates Mitogenesis in 3T3 Cells. J Clin Invest 1993;91:1974-1978.
17. Szakonyi G, Guthridge JM, Li D, et al.: Structure of complement receptor 2 in complex with its C3d ligand. Science 2001;292:1725-1728.
18. Nagar B, Jones RG, Diefenbach RJ, et al.: X-ray crystal structure of C3d: A C3 fragment and ligand for complement receptor 2. Science 1998;280:1277-1281.
19. Clemenza L, Isenman DE: Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21). J Immunol 2000;165:3839-3848.
20. Guthridge JM, Rakstang JK, Young KA, et al.: Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry 2001;40:5931-5941.
21. Guthridge JM, Young K, Gipson MG, et al.: Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J Immunol 2001;167:5758-5766.
22. Smith DL, Deng YZ, Zhang ZQ: Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry. J Mass Spectrom 1997;32:135-146.
23. Mandell JG, Falick AM, Komives EA: Identification of protein-protein interfaces by decreased amide proton solvent accessibility. Proc Natl Acad Sci USA 1998;95:14,705-14,710.
24. Mandell JG, Falick AM, Komives EA: Measurement of amide hydrogen exchange by MALDI-TOF mass spectrometry. Anal Chem 1998;70:3987-3995.
25. Sahu A, Lambris JD: Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 2000;49:133-148.
26. Sahu A, Lambris JD: Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunological Reviews 2001;180:35-48.
27. Sahu A, Kay BK, Lambris JD: Inhibition of human complement by a C3-binding peptide isolated from a phage displayed random peptide library. J Immunol 1996;157:884-891.
28. Soulika AM, Khan MM, Hattori T, et al.: Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol 2000;96:212-221.
29. Fiane AE, Mollnes TE, Videm V, et al.: Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin. Transplant Proc 1999;31:934-935.
30. Fiane AE, Mollnes TE, Videm V, et al.: Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 1999;6:52-65.
31. Fiane AE, Videm V, Lambris JD, et al.: Modulation of fluid-phase complement activation inhibits hyperacute rejection in a porcine-to-human xenograft model. Transplant Proc 2000;32:899-900.
32. Nilsson B, Larsson R, Hong J, et al.: Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998;92:1661-1667.
33. Furlong ST, Dutta AS, Coath MM, et al.: C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alphaketoheterocycles. Immunopharmacology 2000;48:199-212.
34. Morikis D, Assa-Munt N, Sahu A, et al.: Solution structure of compstatin, a potent complement inhibitor. Protein Science 1998;7:619-627.
35. Klepeis JL, Floudas CA, Morikis D, et al.: Predicting peptide structures using NMR data and deterministic global optimization. J Comput Chem 1999;20:1344-1370.
36. Morikis D, Sahu A, Moore WT, et al.: Design, structure, function and application of compstatin in bioactive peptides in drug discovery and design: medical aspects. 1999;235-246.
37. Morikis D, Roy M, Sahu A, et al.: The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR. J Biol Chem 2002;277:14,942-14,953.
38. Sahu A, Soulika AM, Morikis D, et al.: Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J Immunol 2000;165:2491-2499.
39. Lambris JD, Holers VM (eds): Therapeutic interventions in the complement system. Totowa, NJ. Humana, 2000.
40. Sahu A, Morikis D, Lambris JD: Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol 2003;39:557-566.
41. Pennington SR, Wilkins MR, Hochstrasser DF, et al.: Proteome analysis: From protein characterization to biological function. Trends Cell Biol 1997;7:168-173.
42. Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18:533-537.
43. Peng JM, Gygi SP: Proteomics: the move to mixtures. J Mass Spectrom 2001;36:1083-1091.
44. Mastellos D, Papadimitriou JC, Franchini S, et al.: A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol 2001;166:2479-2486.
45. O'Barr SA, Caguioa J, Gruol D, et al.: Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001;166:4154-4162.
46. Sato T, Abe E, Cheng HJ, et al.: The biological roles of the 3rd component of complementin osteoclast formation. Endocrinology 1993;133:397-404.
47. Kotwal GJ, Moss B: Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 1988;335:176-178.
48. Kotwal GJ, Isaacs SN, McKenzie R, et al.: Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 1990;250:827-830.
49. Mckenzie R, Kotwal GJ, Moss B, et al.: Regulation of complement activity by vaccinia virus complement- control protein. J Infect Dis 1992;166:1245-1250.
50. Sahu A, Isaacs SN, Soulika AM, et al.: Interaction of vaccinia virus complement control protein with human complement proteins: Factor I-mediated degradation of C3b to iC3b(1) inactivates the alternative complement pathway. J Immunol 1998;160:5596-5604.
51. Sarrias MR, Franchini S, Canziani G, et al.: Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J Immunol 2001;167:1490-1499.
52. Isaacs SN, Kotwal GJ, Moss B: Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci USA 1992;89:628-632.
53. Albrecht JC, Fleckenstein B: Complement regulatory proteins of herpesvirus saimiri. 1995;127-145.
54. Spear PG: Antigenic structure of herpes simplex viruses. 1985;425-446.
55. McNearney TA, Odell C, Holers VM, et al.: Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement mediated neutralization of viralinfectivity. J Exp Med 1987;166:1525-1535.
56. Friedman HM, Wang L, Fishman NO, et al.: Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J Virol 1996;70:4253-4260.
57. Johnson DC, Spear PG: O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus. Cell 1983;32:987-997.
58. Tal-Singer R, et al.: Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 1995;69:4471-4483.
59. Fries LF, Friedman HM, Cohen GH, et al.: Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol 1986;137:1636-1641.
60. Hung SL, Peng C, Kostavasili I, et al.: The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology 1994;203:299-312.
61. Kostavasil I, Sahu A, Friedman HM, et al.: Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol 1997;158:1763-1771.
62. Friedman HM, Wang L, Pangburn MK, et al.: Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J Immunol 2000;165:4528-4536.
63. Lubinski JM, Wang L, Soulika AM, et al.: Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J Virol 1998;72:8257-8263.
64. Lubinski J, Wang L, Mastellos D, et al.: In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med 1999;190:1637-1646.
65. Cooper NR: Complement evasion strategies of microorganisms. Immunol Today 1991;12:327-331.
66. Nemerow GR, Houghten RA, Moore MD, et al.: Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 1989;56:369-377.
67. Tsoukas CD, Lambris JD: Expression of EBV/C3d receptors on T cells: biological significance. Immunol Today 1993;14:56-59.
68. Ross GD, Newman SL, Lambris JD, et al.: Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med 1983;158:334-352.
69. Kalli KR, Ahearn JM, Fearon DT,: Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J Immunol 1991;147:590-594.
70. Hedrick JA, Lao Z, Wang Y, et al.: Isolation and characterization of Epstein-Barr Virus receptor from a T cell line (HSB2). J Immunol 1994;153:4418-4426.
71. Bergelson JM, Chan M, Solomon KR, et al.: Decay-accelerating factor (CD55), a glycosyl-phosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc Natl Acad Sci USA 1994;91:6245-6249.
72. Manchester M, Liszewski MK, Atkinson JP, et al.: Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci USA 1994;91:2161-2165.
73. Smith LC, Azumi K, Nonaka M: Complement systems in invertebrates. The ancient alternative and lectin pathways. Immunopharmacology 1999;42:107-120.
74. Day NKB, Gewurz H, Johannsen R, et al.: Complement and complement-like activity in lower vertebrates and invertebrates. J Exp Med 1970;132:941-950.
75. Al-Sharif WZ, Sunyer JO, Lambris JD, et al.: Sea urchin coelomocytes specifically express a homoloque of the complement component C3. J Immunol 1997;160:2983-2997.
76. Sunyer JO, Zarkadis IK, Sahu A, et al.: Multiple forms of complement C3 in trout, that differ in binding to complement activators. Proc Natl Acad Sci USA 1996;93:8546-8551.
77. Sunyer JO, Tort L, Lambris JD: Structural C3 diversity in fish - Characterization of five forms of C3 in the diploid fish Spans aurata. J Immunol 1997;158:2813-2821.
78. Marino R, Kimura Y,m De Santis R, et al.: Complement in urochordates: cloning and characterization of two C3-like genes in the ascidian Ciona intestinalis. Immunogenetics 2002;53:1055-1064.
79. Smith SL: Shark complement: an assessment. Immunol Rev 1998;166:67-78.
80. Suzuki MM, Satoh N, Nonaka M: C6-like and c3-like molecules from the cephalochordate, amphioxus, suggest a cytolytic complement system in invertebrates. J Mol Evol 2002;54:671-679.
81. Franchini S, Zarkadis IK, Syfroera G, et al.: Cloning and purification of the rainbow trout fifth component of complement (C5). Dev Comp Immunol 2001;25:419-430.
82. Miyazawa S, Azumi K, Nonaka M: (2001) Cloning and characterization of integrin alpha subunits from the solitary ascidian, halocynthia roretzi. J Immunol 2001;166:1710-1715.
83. Sunyer JO, Zarkadis I, Sarrias MR, et al.: Cloning, structure, and function of two rainbow trout Bf molecules. J Immunol 1998;161:4106-4114.
84. Alsenz J, Becherer JD, Nilsson B, et al.: Structural and functiuonal analysis of C3 using monoclonal antibodies. Curr Top Microbiol Immunol 1989;153:235-248.
85. Kemper C, Zipfel PF, Gigli I: The complement cofactor protein (SBP1) from the barred sand bass (Paralabrax nebulifer) mediates overlapping regulatory activities of both human C4b binding protein and factor H. J Biol Chem 1998;273:19,398-19,404.
86. Fausto N, Webber EM: Liver Regeneration, in The Liver: Biology and Pathobiology (Arias IM, Boyer JL, Fausto N, et al., eds.). 3rd, ed. Raven Press, New York, 1994;1059-1084.
87. Cressman DE, Greenbaum LE, DeAngelis RA, et al.: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996;274:1379-1383.
88. Yamada Y, Kirillova I, Peschon JJ, et al.: Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997;94:1441-1446.
89. Taub R, Greenbaum LE, Peng Y: Transcriptional regulatory signals define cytokine-dependent and - independent pathways in liver regeneration. Semin Liver Dis 1999;19:117-127.
90. Finch AM, Wong AK, Paczkowski NJ, et al.: Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 1999;42:1965-1974.
91. Brockes JP: Amphibian limb regeneration: rebuilding a complex structure. Science 1997;276:81-87.
92. Tsonis PA: Amphibian limb regeneration In vivo. 1991;5:541-550.
93. Tsonis PA: Regeneration in vertebrates. Dev Biol 2000;221:273-284.
94. Del Rio-Tsonis K, Tsonis PA, Zarkadis IK, et al.: Expression of the third component of complement, C3, in regenerating limb blastema cells of urodeles. J Immunol 1998;161:6819-6824.
95. Sun X, Funk CD, Deng C, et al.: Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA 1999;96:628-633.
96. Petrenko O, Beavis A, Klaine M, et al.: The molecular characterization of the fetal stem cell marker AA4. Immunity 1999;10:691-700.
97. Dean YD, McGreal EP, Gasque P.: Endothelial cells, megakary-oblasts, platelets and alveolar epithelial cells express abundant levels of the mouse AA4 antigen, a C-type lectin-like receptor involved in homing activities and innate immune host defense. Eur J Immunol 2001;31:1370-1381.
98. Zou YR, Kottmann AH, Kuroda M, et al.: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-599.